Sutro Biopharma Halves Workforce Amid Leadership Changes
SOURCENews reportView the filing ↗
What we know
Based on news reporting.
Summary
Sutro Biopharma, Inc. has announced significant layoffs, cutting its workforce by half. This decision comes alongside the departure of its CEO and the discontinuation of its lead antibody-drug conjugate (ADC) program. The company is undergoing a restructuring process to streamline operations and focus on its core projects. The layoffs reflect Sutro's strategic shift in response to current market conditions and internal assessments of its business direction. This move is part of a broader trend in the biotech industry as companies reassess their workforce amid economic challenges.
LayoffTalk has tracked 6 layoff events at Sutro Biopharma, Inc. since March 2025, including 119 jobs documented in official WARN filings, with 4 additional events known from news reporting.
Comments (0)
Anonymous by default. Be kind — people reading this may be going through it right now.
No comments yet. Be the first to share your thoughts.
Affected by this?
Share your story anonymously — it helps others reading this feel less alone.
Share your story →More layoffs at Sutro Biopharma, Inc.
Recent tracked events at this company.